Jul 02

M.M DILLON & CO SERVES AS FINANCIAL ADVISOR TO CONTRAFECT CORPORATION IN ITS UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

MM Dillon acted as a financial advisor to ContraFect Corporation (CFRX), in its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares of common stock with an exercise price of $1.55 per share at a combined public offering price of $1.25 per share and related warrant. All shares and warrants in the offering were sold by ContraFect. The gross proceeds from the offering was $40.0 million.

About ContraFect Corporation

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The company’s most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of monoclonal antibodies for the treatment of seasonal and pandemic varieties of influenza. The proceeds from the private placement will be used to fund Phase 2 clinical trials for CF-301 for staph bloodstream infections, IND-enabling activities for CF-404 for serious influenza and other corporate purposes.

About M.M. Dillon & Co.

M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.

Leave a reply

Your email address will not be published. Required fields are marked *